Semiquantitative analysis of the biodistribution of the combined 18F-NaF and 18F-FDG administration for PET/CT imaging

Ryogo Minamimoto, Camila Mosci, Mehran Jamali, Amir Barkhodari, Frezghi Habte, Tatianie Jackson, Erik Mittra, Sanjiv Sam Gambhir, Andrei Iagaru

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In this study, we evaluated the biodistribution of the 18F-/18F-FDG administration, compared with separate 18F-NaF and 18F-FDG administrations. We also estimated the interaction of 18F-NaF and 18F-FDG in the 18F-/18F-FDG administration by semiquantitative analysis. Methods: We retrospectively analyzed the data of 49 patients (39 men, 10 women; mean age ± SD, 59.3 ± 15.2 y) who underwent separate 18F-FDG PET/CT and 18F-NaF PET/CT scans as well as 18F-/18F-FDG PET/CT sequentially. The most common primary diagnosis was prostate cancer (n 5 28), followed by sarcoma (n 5 9) and breast cancer (n 5 6). The mean standardized uptake values (SUVs) were recorded for 18 organs in all patients, and maximum SUV and mean SUV were recorded for all the identified malignant lesions. We also estimated the 18F-/18F-FDG uptake as the sum of18F-FDG uptake and adjusted 18F-NaF uptake based on the ratio of18F-NaF injected dose in 18F-/18F-FDG PET/CT. Lastly, we compared the results to explore the interaction of 18F-FDG and18F-NaF uptake in the 18F-/18F-FDG scan. Results: The18F-/18F-FDG uptake in the cerebral cortex, cerebellum, parotid grand, myocardium, and bowel mostly reflected the18F-FDG uptake, whereas the uptake in the other analyzed structures was influenced by both the 18F-FDG and the 18F-NaF uptake. The 18F-/18F-FDG uptake in extraskeletal lesions showed no significant difference when compared with the uptake from the separate18F-FDG scan. The18F-/18F-FDG uptake in skeletal lesions reflected mostly the 18F-NaF uptake. The tumor-to-background ratio of 18F-/18F-FDG in extraskeletal lesions showed no significant difference when compared with that from 18F-FDG alone (P 5 0.73). For skeletal lesions, the tumor-to-background ratio of 18F-/18F-FDG was lower than that from 18F-NaF alone (P , 0.001); however, this difference did not result in missed skeletal lesions on the 18F-/18F-FDG scan. Conclusion: The understanding of the biodistribution of radiopharmaceuticals and the lesion uptake of the 18F-/18F-FDG scan as well as the variations compared with the uptake on the separate 18F-FDG PET/CT and 18F-NaF PET/CT are valuable for more in-depth evaluation of the combined scanning technique.

Original languageEnglish (US)
Pages (from-to)688-694
Number of pages7
JournalJournal of Nuclear Medicine
Volume56
Issue number5
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Radiopharmaceuticals

Keywords

  • <sup>18</sup>f-fdg
  • <sup>18</sup>f-naf
  • PET/CT
  • SUV

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Semiquantitative analysis of the biodistribution of the combined 18F-NaF and 18F-FDG administration for PET/CT imaging. / Minamimoto, Ryogo; Mosci, Camila; Jamali, Mehran; Barkhodari, Amir; Habte, Frezghi; Jackson, Tatianie; Mittra, Erik; Gambhir, Sanjiv Sam; Iagaru, Andrei.

In: Journal of Nuclear Medicine, Vol. 56, No. 5, 01.01.2015, p. 688-694.

Research output: Contribution to journalArticle

Minamimoto, R, Mosci, C, Jamali, M, Barkhodari, A, Habte, F, Jackson, T, Mittra, E, Gambhir, SS & Iagaru, A 2015, 'Semiquantitative analysis of the biodistribution of the combined 18F-NaF and 18F-FDG administration for PET/CT imaging', Journal of Nuclear Medicine, vol. 56, no. 5, pp. 688-694. https://doi.org/10.2967/jnumed.115.153767
Minamimoto, Ryogo ; Mosci, Camila ; Jamali, Mehran ; Barkhodari, Amir ; Habte, Frezghi ; Jackson, Tatianie ; Mittra, Erik ; Gambhir, Sanjiv Sam ; Iagaru, Andrei. / Semiquantitative analysis of the biodistribution of the combined 18F-NaF and 18F-FDG administration for PET/CT imaging. In: Journal of Nuclear Medicine. 2015 ; Vol. 56, No. 5. pp. 688-694.
@article{5c261da01a6b4f0a828351c81b3afaf3,
title = "Semiquantitative analysis of the biodistribution of the combined 18F-NaF and 18F-FDG administration for PET/CT imaging",
abstract = "In this study, we evaluated the biodistribution of the 18F-/18F-FDG administration, compared with separate 18F-NaF and 18F-FDG administrations. We also estimated the interaction of 18F-NaF and 18F-FDG in the 18F-/18F-FDG administration by semiquantitative analysis. Methods: We retrospectively analyzed the data of 49 patients (39 men, 10 women; mean age ± SD, 59.3 ± 15.2 y) who underwent separate 18F-FDG PET/CT and 18F-NaF PET/CT scans as well as 18F-/18F-FDG PET/CT sequentially. The most common primary diagnosis was prostate cancer (n 5 28), followed by sarcoma (n 5 9) and breast cancer (n 5 6). The mean standardized uptake values (SUVs) were recorded for 18 organs in all patients, and maximum SUV and mean SUV were recorded for all the identified malignant lesions. We also estimated the 18F-/18F-FDG uptake as the sum of18F-FDG uptake and adjusted 18F-NaF uptake based on the ratio of18F-NaF injected dose in 18F-/18F-FDG PET/CT. Lastly, we compared the results to explore the interaction of 18F-FDG and18F-NaF uptake in the 18F-/18F-FDG scan. Results: The18F-/18F-FDG uptake in the cerebral cortex, cerebellum, parotid grand, myocardium, and bowel mostly reflected the18F-FDG uptake, whereas the uptake in the other analyzed structures was influenced by both the 18F-FDG and the 18F-NaF uptake. The 18F-/18F-FDG uptake in extraskeletal lesions showed no significant difference when compared with the uptake from the separate18F-FDG scan. The18F-/18F-FDG uptake in skeletal lesions reflected mostly the 18F-NaF uptake. The tumor-to-background ratio of 18F-/18F-FDG in extraskeletal lesions showed no significant difference when compared with that from 18F-FDG alone (P 5 0.73). For skeletal lesions, the tumor-to-background ratio of 18F-/18F-FDG was lower than that from 18F-NaF alone (P , 0.001); however, this difference did not result in missed skeletal lesions on the 18F-/18F-FDG scan. Conclusion: The understanding of the biodistribution of radiopharmaceuticals and the lesion uptake of the 18F-/18F-FDG scan as well as the variations compared with the uptake on the separate 18F-FDG PET/CT and 18F-NaF PET/CT are valuable for more in-depth evaluation of the combined scanning technique.",
keywords = "<sup>18</sup>f-fdg, <sup>18</sup>f-naf, PET/CT, SUV",
author = "Ryogo Minamimoto and Camila Mosci and Mehran Jamali and Amir Barkhodari and Frezghi Habte and Tatianie Jackson and Erik Mittra and Gambhir, {Sanjiv Sam} and Andrei Iagaru",
year = "2015",
month = "1",
day = "1",
doi = "10.2967/jnumed.115.153767",
language = "English (US)",
volume = "56",
pages = "688--694",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "5",

}

TY - JOUR

T1 - Semiquantitative analysis of the biodistribution of the combined 18F-NaF and 18F-FDG administration for PET/CT imaging

AU - Minamimoto, Ryogo

AU - Mosci, Camila

AU - Jamali, Mehran

AU - Barkhodari, Amir

AU - Habte, Frezghi

AU - Jackson, Tatianie

AU - Mittra, Erik

AU - Gambhir, Sanjiv Sam

AU - Iagaru, Andrei

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In this study, we evaluated the biodistribution of the 18F-/18F-FDG administration, compared with separate 18F-NaF and 18F-FDG administrations. We also estimated the interaction of 18F-NaF and 18F-FDG in the 18F-/18F-FDG administration by semiquantitative analysis. Methods: We retrospectively analyzed the data of 49 patients (39 men, 10 women; mean age ± SD, 59.3 ± 15.2 y) who underwent separate 18F-FDG PET/CT and 18F-NaF PET/CT scans as well as 18F-/18F-FDG PET/CT sequentially. The most common primary diagnosis was prostate cancer (n 5 28), followed by sarcoma (n 5 9) and breast cancer (n 5 6). The mean standardized uptake values (SUVs) were recorded for 18 organs in all patients, and maximum SUV and mean SUV were recorded for all the identified malignant lesions. We also estimated the 18F-/18F-FDG uptake as the sum of18F-FDG uptake and adjusted 18F-NaF uptake based on the ratio of18F-NaF injected dose in 18F-/18F-FDG PET/CT. Lastly, we compared the results to explore the interaction of 18F-FDG and18F-NaF uptake in the 18F-/18F-FDG scan. Results: The18F-/18F-FDG uptake in the cerebral cortex, cerebellum, parotid grand, myocardium, and bowel mostly reflected the18F-FDG uptake, whereas the uptake in the other analyzed structures was influenced by both the 18F-FDG and the 18F-NaF uptake. The 18F-/18F-FDG uptake in extraskeletal lesions showed no significant difference when compared with the uptake from the separate18F-FDG scan. The18F-/18F-FDG uptake in skeletal lesions reflected mostly the 18F-NaF uptake. The tumor-to-background ratio of 18F-/18F-FDG in extraskeletal lesions showed no significant difference when compared with that from 18F-FDG alone (P 5 0.73). For skeletal lesions, the tumor-to-background ratio of 18F-/18F-FDG was lower than that from 18F-NaF alone (P , 0.001); however, this difference did not result in missed skeletal lesions on the 18F-/18F-FDG scan. Conclusion: The understanding of the biodistribution of radiopharmaceuticals and the lesion uptake of the 18F-/18F-FDG scan as well as the variations compared with the uptake on the separate 18F-FDG PET/CT and 18F-NaF PET/CT are valuable for more in-depth evaluation of the combined scanning technique.

AB - In this study, we evaluated the biodistribution of the 18F-/18F-FDG administration, compared with separate 18F-NaF and 18F-FDG administrations. We also estimated the interaction of 18F-NaF and 18F-FDG in the 18F-/18F-FDG administration by semiquantitative analysis. Methods: We retrospectively analyzed the data of 49 patients (39 men, 10 women; mean age ± SD, 59.3 ± 15.2 y) who underwent separate 18F-FDG PET/CT and 18F-NaF PET/CT scans as well as 18F-/18F-FDG PET/CT sequentially. The most common primary diagnosis was prostate cancer (n 5 28), followed by sarcoma (n 5 9) and breast cancer (n 5 6). The mean standardized uptake values (SUVs) were recorded for 18 organs in all patients, and maximum SUV and mean SUV were recorded for all the identified malignant lesions. We also estimated the 18F-/18F-FDG uptake as the sum of18F-FDG uptake and adjusted 18F-NaF uptake based on the ratio of18F-NaF injected dose in 18F-/18F-FDG PET/CT. Lastly, we compared the results to explore the interaction of 18F-FDG and18F-NaF uptake in the 18F-/18F-FDG scan. Results: The18F-/18F-FDG uptake in the cerebral cortex, cerebellum, parotid grand, myocardium, and bowel mostly reflected the18F-FDG uptake, whereas the uptake in the other analyzed structures was influenced by both the 18F-FDG and the 18F-NaF uptake. The 18F-/18F-FDG uptake in extraskeletal lesions showed no significant difference when compared with the uptake from the separate18F-FDG scan. The18F-/18F-FDG uptake in skeletal lesions reflected mostly the 18F-NaF uptake. The tumor-to-background ratio of 18F-/18F-FDG in extraskeletal lesions showed no significant difference when compared with that from 18F-FDG alone (P 5 0.73). For skeletal lesions, the tumor-to-background ratio of 18F-/18F-FDG was lower than that from 18F-NaF alone (P , 0.001); however, this difference did not result in missed skeletal lesions on the 18F-/18F-FDG scan. Conclusion: The understanding of the biodistribution of radiopharmaceuticals and the lesion uptake of the 18F-/18F-FDG scan as well as the variations compared with the uptake on the separate 18F-FDG PET/CT and 18F-NaF PET/CT are valuable for more in-depth evaluation of the combined scanning technique.

KW - <sup>18</sup>f-fdg

KW - <sup>18</sup>f-naf

KW - PET/CT

KW - SUV

UR - http://www.scopus.com/inward/record.url?scp=84929456902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929456902&partnerID=8YFLogxK

U2 - 10.2967/jnumed.115.153767

DO - 10.2967/jnumed.115.153767

M3 - Article

VL - 56

SP - 688

EP - 694

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 5

ER -